OBJECTIVES: Transcatheter mitral valved stent implantation provides an off-pump treatment option for mitral valve regurgitation, especially for secondary mitral valve regurgitation. The aim of this study was to evaluate novel fixation strategies: direct fixation (SUPRA) and subvalvular fixation (sub-VALV) to successfully implement alternative fixation methods at the mitral annulus and to reduce radial stent and apical tether forces.
INTRODUCTION
At the moment, transcatheter mitral valve implantation (TMVI) is the subject of intense research [1] . In recent years, different prosthesis designs have been presented, tested in vivo in experimental studies [2] [3] [4] [5] [6] [7] and implanted in 'first-in-man' studies [8] [9] [10] [11] [12] [13] [14] [15] (Table  1 ). The first-in-man on-pump implantation of a TMVI device was performed in 2012 [12] , followed by further early in-man studies off-pump in 2013 [6] and 2014 [8, 10] . The individual prototypes are based on different fixation mechanisms and designs. The Tendyne TMVI device [15] [16] [17] [18] and the prototypes previously presented by our group [4, 5, 19] include an apical tether fixation system. Other designs such as the design of the Tiara [2] , the CardiAQ [20, 21] , the Fortis valved stent [22] and designs previously presented by our group [3, 5] include subannular and subvalvular fixation elements to achieve systolic fixation. The early clinical feasibility trials have shown promising results [8, 14, 15, 20, 21] .
Challenges in the developmental process of such mitral valved stents include secure fixation within the complex anatomy of the mitral valve apparatus, high pressure acting within the left heart, the absence of a left ventricular outflow tract (LVOT) obstruction and tight sealing to prevent the occurrence of paravalvular leakages (PVLs). In this study, new fixation options were tested: besides the apical tether (the AP group), the direct supra-annular fixation technique (the SUPRA group) and subannular fixation technique (the sub-VALV group) were tested as an alternative means of achieving valved stent fixation within the mitral annulus. The aim of this study was to evaluate these fixation techniques for TMVI in an in vivo porcine model.
METHODS

Mitral valved stent design
Prior designs were based on a transapical fixation technique or a subannular fixation technique [4, 5] . In this study, novel concepts of additional supra-annular (SUPRA) and subvalvular (sub-VALV) fixations were compared with the sole apical valved stent fixation (AP). The design process was assisted by computer-aided design programmes and finite element method (FEM) simulation, including data from a cardiac computed tomography (CT) evaluation of patients with mitral valve regurgitation, rapid prototype models and in vitro testing.
The basis of the 1st optimized supra-annular fixation concept (Design SUPRA) was the development of elements to fix the mitral valved stent onto the surrounding tissue on the atrial side. Thereto, a specifically designed platform-hook concept was developed (Fig. 1) . The hook was manufactured by Kern (Kern Micro-und Feinwerktechnik GmbH & Co. Kg, Murnau-Westried, Germany).
The mitral valved stent comprised an anatomical nitinol stent frame (RTM, Graben-Neudorf, Germany), which covered with a polytetrafluoroethylene (Zeus Inc., SC, USA) membrane and a trileaflet bioprosthetic valve. Furthermore, it serves as a platform to mount the hooks. Three or 4 individual hooks (3 hooks: n = 2; 4 hooks: n = 3) were mounted on each stent at the annular edge, and a thread system (4-0 Prolene, Ethicon Inc., NJ, USA) was then attached to enable deployment within the heart (Fig. 2 ). An apical fixation system consisting of 4 individual neochords was attached to the basic ventricular rim of the stent [4, 19] to secure the initial position.
The 2nd fixation design included subvalvular fixation elements (Design sub-VALV). A modified nitinol valved stent with a ventricular rim was developed, optimized and tested in 4 anatomically adapted iterations (Fig. 3) . The stents comprised a nitinol stent frame (RTM), which covered with a polytetraofluoroethylene (Zeus Inc.) membrane and a trileaflet bioprosthetic valve. A modified D-shape was developed. On the ventricular side, the fixation ring was connected to the annular body at 45
. The inner diameter of the annular stent body was 28 mm. To secure the initial position, an apical fixation system was attached to these stents.
These new TMVI concepts were compared with the prototype design of a mitral valved stent consisting of an atrial element connected to the annular element at 110 with sole apical fixation (AP) as presented previously [4] .
Animal model
The experimental implantations were carried out in a wellestablished porcine model [4, 5] . Thirty-three German Landrace swine, Edelschwein or their cross-breeds with an average body weight of 49 ± 4 kg underwent transapical off-pump mitral valved stent implantation [Group SUPRA: n = 5 and 2 of them (2 of 7) died during preimplantation, Group sub-VALV: n = 10 and group sole AP: n = 16]. Notably, these animals included those that were already reported on (Design sole AP) and are presented as a reference in this study. All animals received humane care in compliance with the 'Guide for the Care and Use of Laboratory Animals' prepared by the Institute of Laboratory Animal Resources and revised in 2011.
Implantation of the valved stents
The implantation procedure via a lower ministernotomy has been previously described [4, 5] . It grants access to the apex of the heart in the porcine model under total intravenous anaesthesia, intermittent positive pressure ventilation, electrocardiography and invasive measurement of blood pressures.
The valved nitinol stent carrying the hooks was crimped into the delivery system, introduced through the apex of the heart and implanted into the mitral annulus under 2-dimensional and 3-dimensional transoesophageal echocardiographic guidance (GE Vivid-i V R , England and Philips iE33 xMatrix, TOEProbe X7-2t). The stents were then released in a multi-step procedure (Videos 1 and 2). Following deployment, the ventricular fixation system was knotted against a counter-bearing (PET button on the epicardial side) at the purse-string suture in the apex. 
Measurements
A full haemodynamic and echocardiographic evaluation was performed before and 1 h after valved stent implantation according to a standardized protocol. The echocardiographic evaluation was conducted in standard as well as non-standard views [23] .
Follow-up
When haemodynamic stability was achieved, the animals were weaned from anaesthesia and brought back to the animal facility for a follow-up period of 1 and 3 months. Identical follow-up was conducted in all groups. After 1 month, echocardiography, ventriculography and cardiac CT were performed. The follow-up period was prolonged for a further month up to a total of 3 months if the animals were in excellent health. Otherwise, euthanasia was performed in deep anaesthesia. Gross evaluation was performed after euthanasia of animals and focused on stent position, subannular fixation elements (area and height), possible obstruction of the LVOT and occurrence of stent fractures.
Statistical analysis
Statistical analysis was performed using SPSS 24 (SPSS Software, Germany). All results are expressed as means ± standard deviation. Significant differences of haemodynamic and echocardiographic parameters after valved stent implantation within the groups were identified using the Wilcoxon rank-sum test. Differences between the groups were detected using the MannWhitney U-test. The homogeneity of variances was tested using the Levenes' test. The probability of a Type I error was set to 5% (a = 0.05).
RESULTS
The stents of the 3 groups were successfully deployed in 31 animals in total. Two animals (of the SUPRA group, aforementioned 33 implantations) died prior to stent implantation due to ventricular fibrillation and were excluded from the study (see overview in Tables 2-5 ).
Design SUPRA
The Design SUPRA with supra-annular hook-shaped fixation elements was successfully implanted in 5 animals (Table 2) . Nevertheless, 1 animal died at the end of the day due to patientprosthesis mismatch. Four animals were weaned successfully from anaesthesia, followed up and found to be in good health. One animal was sacrificed after 2 weeks, and 3 animals were followed up for a period of at least 1 month at excellent well-being. Two animals were sacrificed after the 1-month follow-up evaluation, and 1 animal was followed up for another 2 months and was sacrificed after 3 months of follow-up in excellent health. No sustained or haemodynamic relevant arrhythmias were recorded in the surviving animals (0 of 5). The fixation hooks were successfully deployed in all but 1 case. 
Design sub-VALV
The anatomical prototype sub-VALV with subvalvular fixation elements was successfully implanted in all 10 animals ( Table 2) . In this group, multiple infarction areas and arrhythmia were observed after implantation: ventricular fibrillation occurred in this group after valved stent implantation in 4 of 10 cases (P = 0.037 vs other study groups) but were reconverted very soon to sinus rhythm. Persistent atrial fibrillation after stent implantation occurred in 1 case. Eight animals were analysed after 6 h and died within the 1st day. Nevertheless, 2 animals were weaned from anaesthesia and were followed up for a period of 2 and 7 days. A reduction in left ventricular ejection fraction was observed when compared with baseline values (P < 0.05) in this study group.
Prototype AP with apical fixation
In the group of Design AP with sole apical fixation, 16 animals successfully underwent the TMVI procedure. Thirteen animals were weaned from anaesthesia and were further followed up ( Table 2 ): 7 of these animals were followed up for a period of 1 month and found to be in excellent health. Five of them were Statistical analysis of the SUPRA and sub-VALV groups was performed using the Wilcoxon rank-sum test. In the AP group, the dependent Student's t-test was conducted. sacrificed after the 1-month evaluation, and 1 animal was observed for another month. One animal was of deteriorating health condition within the 4th postoperative week. Six animals died within the first 2 postoperative weeks. In 1 case, atrial fibrillation occurred following the stent implantation (1 of 16). In only 1 case, a suture of the TMVI device ruptured, leading to massive regurgitation due to failure of the valved stent.
Echocardiographic evaluation
Echocardiographic evaluation (Tables 3 and 5 ) of the mean gradients across the mitral valved stent, LVOT and aortic valve were within a physiological range at all points of time, except in the sub-VALV group where the LVOT data were not recorded. The mean gradients and maximal velocities across the valved stent, LVOT and aortic valve increased mildly after stent implantation (P < 0.05) in the AP group. In the sub-VALV group, the maximal velocities and mean gradient across the mitral valve were also mildly increased (P < 0.05). Nevertheless, the values remained within physiological ranges. No changes in the echocardiographic and haemodynamic parameters following mitral valved stent implantation were observed in the SUPRA group (P = NS). PVLs (Table 4) were mild or less in the AP design. In contrast, the SUPRA design indicated no PVL in all 5 cases. In the sub-VALV group, PVLs were mild or more in all 10 cases. Central mitral regurgitation was present at a low degree in all groups. Echocardiographic evaluation of the LVOT (Table 3) revealed an increased LVOT obstruction in the sub-VALV group when compared with the SUPRA (P = 0.026) and AP groups (P = 0.014).
The LVOT obstruction was 40% or more in 3 of 8 cases in the sub-VALV group. Nevertheless, in 1 case of the AP group, the LVOT was also moderately obstructed (Table 3) .
Haemodynamic evaluation
Haemodynamic evaluation (Table 5 ) indicated an increased mean arterial pressure in the SUPRA group when compared with the AP group (P = 0.011). In the sub-VALV group, the central venous pressure increased after valved stent implantation (P < 0.05). The mean arterial pressure and the pulmonary artery pressure (PAP) were higher after valved stent implantation in the AP group (P < 0.05). No significant differences for the pulmonary capillary wedge pressure (PCWP) data were observed, even though a mild trend towards an increasing PCWP was observed in the SUPRA group. Nevertheless, all measured pressures remained in the physiological range.
Gross evaluation
In the sub-VALV group, an adequate position of the ventricular elements was achieved in all 8 cases. However, the annular height of this design was slightly too high causing a positioning of the atrial element towards the annulus and a mild LVOT obstruction in 50% of all cases. The ventricular elements caused mild damage (macroscopic lesions) of the surrounding tissue of the left ventricle.
Gross evaluation of the SUPRA design showed a good ingrowth of the valved stent after 1 month and later (n = 4). The atrial element was 95 ± 5% covered by tissue (when compared with 92 ± 7% in the sole group) and a strong ingrowth into the surrounding tissue was achieved in 61 ± 41% (vs 57 ± 27% in the AP group). All hooks were deployed; however, only 14 of 18 hooks were completely anchored within the tissue. Fractures of the nitinol stent in the proximity of the hook elements were observed in 3 of the cases. In only 1 case, surrounding structures were penetrated by one of the hooks (into RA and aortic root).
The AP design achieved correct stent deployment and excellent stent position in 14 of 16 cases. In 1 case, the implantation position was too high, and in one of the cases, the valve tether was loosened. Minor stent fractures of single struts were observed in 3 cases.
Even though individual neochords of the apical fixation system ruptured in 3 cases throughout the entire observation period of 1 month or more, stable stent position was achieved in these cases.
DISCUSSION
This study focussed on evaluating new fixation techniques. Hence, supra-annular and subvalvular fixation elements for mitral valved stent fixation were evaluated in an in vivo porcine model: we believe that a combination of apical and annular fixation may show the most promising results (Fig. 1) . The advantage of the Statistical analysis of the SUPRA and sub-VALV groups was performed using the Wilcoxon rank-sum test. In the AP group, the dependent Student's t-test was conducted.
a Differences after valved stent implantation (P < 0.05). MAP: mean arterial pressure; PAP: pulmonary artery pressure; PCPW: pulmonary capillary wedge pressure; RAP: right atrial pressure; RV: right ventricle.
apical fixation and the advantage of the alternative fixation strategies can be combined. In the near future, both transfemoral approach and transapical approach for TMVI will be provided and used. Correct stent position and good valvular function were not optimally achieved in 6 of 31 cases. The mean gradients across the mitral valved stent, LVOT and aortic valve were within physiological ranges at all times for the SUPRA and AP groups. Unfortunately, not all data are available from the sub-VALV group. Good paravalvular sealing was achieved with minimal to no PVL in the SUPRA and AP groups. In contrast, the sub-VALV group showed trace to severe PVLs. This is of great importance as PVL is directly linked to patient well-being.
The left ventricular function was assessed following the recommendations of the American Society of Echocardiography. The left ventricular ejection fraction was > _50% in all cases showing a good contractility of the left ventricle. Nevertheless, a mild reduction was observed in the sub-VALV group. The transmitral velocity profile (E/A) showed physiological values. The parameter E/ E 0 of the porcine model differs from that of humans, where an average E/E 0 ratio < _8 is associated with patients with normal left ventricular (LV) filling pressures. Nevertheless, the E/É showed a mild pathological trend after valved stent implantation in all groups. These results do not allow for a causal diagnosis, but the pathological change could indicate a mild disturbance of left ventricular diastolic function.
Notable differences were observed between the groups: the 2nd design includes subvalvular fixation elements; in this sub-VALV group, multiple infarction areas and arrhythmia were observed due to the lateral struts interfering with the left ventricle. These side struts caused a too high valved stent positioning towards the annulus, higher PVL rate, lower LV function and small damages near the left ventricular wall.
However, a good alignment of the valved stent design within the left ventricle without obstruction or bulk material hindering heart movement is of utmost importance for the overall outcome and was attained in the SUPRA and AP groups. In contrast, this was not achieved in the sub-VALV group.
The first design with supra-annular hook-shaped elements (the SUPRA group) showed excellent long-term stent function with 3 of 5 devices being followed up for a period of 1 up to 3 months with excellent health of the animals. Echocardiographic and haemodynamic evaluation demonstrated good valve and normal left ventricular function. However, in 1 of 5 cases, the surrounding tissue was partly penetrated by the hook-shaped elements. This side effect must be avoided by better positioning of the hooks on the valved stent itself more towards the annulus. An increased risk of uncontrolled tissue damage is associated with the rotational movement of the hook-shaped elements during the deployment process. Nevertheless, the hook-shaped elements provide a novel and unique fixation strategy for mitral valved stents; therefore, this concept of hook-shaped elements will be further improved. A better defined device position and deployment strategy for these small hooks will help to further reduce any complications. In addition, we believe that helically deployed elements may be also suited to achieve a supraannular fixation of valved stents. This is supported by the good results of other designs.
Limitations
Because of ethical and financial reasons, the study design is limited: 1 of the 3 study groups has a small number of study animals (n = 5). In contrast, the other 2 study groups have more recorded animals (n > _ 10).
CONCLUSION
In conclusion, secure deployment and correct position of the newly designed anatomical mitral valved stents were achieved in the majority of cases. The low degree of PVL in the SUPRA and APICAL groups and the normal longitudinal function highlight the good alignment within the native anatomy. In addition, the effect of stent design on heart function is clearly shown: only in the sub-VALV group with ventricular fixation elements lateral struts were not well tolerated in the hearts. An increased rate of ischaemia and arrhythmia was observed. A shorter lateral strut design might reduce these difficulties.
The novel, hook-shaped, supra-annular fixation elements were well tolerated in the hearts resulting in excellent health of the animals and long follow-up times.
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